EXEL vs QGEN
Exelixis, Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EXEL | QGEN |
|---|---|---|
| Revenue | $2.3B | $2.1B |
| Net income | $782.6M | $424.9M |
| Gross margin | 96.4% | 62.2% |
| Net margin | 33.7% | 20.3% |
| Return on equity | 35.5% | 11.6% |
| Diluted EPS | $2.78 | $1.94 |
| Dividend / share | — | $0.25 |
| Payout ratio | — | 12.8% |
| Free cash flow | $875.8M | $453.3M |
| Equity | $2.2B | $3.8B |
| Net debt / equity | −0.66× | 0.22× |
| Current ratio | 3.56× | 3.90× |
| Revenue CAGR 5y | 18.6% | 2.2% |
| Profit CAGR 5y | 47.6% | 3.4% |
EXEL and QGEN book revenue within 15% of each other, and keeps more of each dollar of revenue as profit (33.7% against 20.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | EXEL | QGEN |
|---|---|---|
| FY2025 | $2.3B | $2.1B |
| FY2024 | $2.2B | $2.0B |
| FY2023 | $1.8B | $2.0B |
| FY2022 | $1.6B | $2.1B |
| FY2021 | $1.4B | $2.3B |
| FY2020 | $987.5M | $1.9B |
| FY2019 | $967.8M | $1.5B |
| FY2018 | $853.8M | $1.5B |
| FY2017 | $452.5M | $1.4B |
| FY2016 | $191.5M | $1.3B |
Net income by year
Bottom line
| Fiscal year | EXEL | QGEN |
|---|---|---|
| FY2025 | $782.6M | $424.9M |
| FY2024 | $521.3M | $83.6M |
| FY2023 | $207.8M | $341.3M |
| FY2022 | $182.3M | $423.2M |
| FY2021 | $231.1M | $512.6M |
| FY2020 | $111.8M | $359.2M |
| FY2019 | $321.0M | $-41.5M |
| FY2018 | $690.1M | $190.4M |
| FY2017 | $154.2M | $40.4M |
| FY2016 | $-70.2M | $80.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry